The United States opioid crisis has wrought devastation on a massive scale. With closure elusive, much of the blame has fallen on a single pill, a long-acting oxycodone tablet called OxyContin. Perhaps one of the most notorious prescription painkillers on the market, OxyContin may be the best documented opioid in the country due to extensive litigation, regulation, and news coverage. Analyses of these documents can provide deeper insights into the drug's lifecycle as well as the shaping of public understandings of the crisis. Blame pervades our lived experiences, affecting how we norm and punish, explain and evade, reconcile and heal. This phenomenon has rarely been discussed by scholars, leaving gaps in our collective knowledge.Drawing on extensive documentation--from media coverage and court records to internal company emails--Madson examines who was blamed, how, and why. To do this, he has adapted for a new critical contextualized methodology to identify key players, map time-space axes, and pinpoint tipping points. Rather than pointing to a single cause, The Rise and Fall of Original OxyContin traces how blame shifted among drug makers, regulators, doctors, patients, and others over time, leaving some as scapegoats. Using clear, accessible language, it offers insight into how blame can influence public health, policy, and trust. The outcome is a preliminary model of blame discourse in pharmaceutical contexts, which aims to inform future research. Applications can be drawn to three critical areas of practice: pharmaceutical risk communication, organizational health literacy, and interprofessional education. The work provides valuable insights into the origins of miscommunication about risk, addiction, and corporate responsibility, and offers practical takeaways for future crisis communication and risk regulation.
Perhaps one of the most notorious prescription painkillers on the market, OxyContin may be the best documented opioid in the country. The Rise and Fall of Original OxyContin traces how blame shifted among drug makers, regulators, doctors, patients, and others over time, leaving some as scapegoats.
